Allergy Shots Market by Product (SLIT Tablets, Oral, Injections)
Industry: Healthcare
Published Date: February-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 309
Report ID: PMRREP31924
The global revenue from the Allergy Shots Market was around US$ 2.2 Billion in 2022, with the global market expected to grow at a CAGR of 10.4% to reach a valuation of around US$ 6.4 Billion by the end of 2033.
|
Market Size (2023) |
US$ 2.4 Billion |
|
Projected Market Value (2033) |
US$ 6.4 Billion |
|
Global Market Growth Rate (2023 to 2033) |
10.4% CAGR |
|
Market Share of Top 5 Countries |
50.9% |
As assessed by Persistence Market Research, injections held a market share of around 66.1% in the global market, in 2022. Overall, allergy shots market sales account for around 44.1% of revenue share in the global allergy diagnostics market, which was valued at around US$ 4.98 Billion in 2022.
The global market recorded a historic CAGR of 8.8% in the last 7 years from 2015 to 2022.
An allergic reaction is the body's immune system reacting to something that most other people do not find bothersome. Allergies may develop when a person's body reacts to environmental elements that are normally safe for most individuals. Dust mites, pollen, pets, insects, mould, ticks, foods, and some medications all include allergen-causing substances.
Allergy symptoms can vary in intensity from mild (rash or hives) to potentially fatal (itching, runny nose, and watery/red eyes). An allergy can always be treated in many ways depending on what the person is sensitive to. Pharmacies provide over-the-counter treatments for persons with minor allergies. Antihistamine-class medications are widely used to treat allergies. Decongestants are a temporary form of therapy.
Skin which developed redness and itching as a result of an allergic reaction is treated with creams and lotions. Steroids can be used to reduce the inflammation caused by an adverse reaction. Seasonal allergies can be treated with natural therapies, over-the-counter (OTC) drugs, and prescription medications.
The allergy shots reduce the sensitivity. For instance, if a person is suffering from any allergy the immune system overreacts, treating a harmless substance as a threat. Elements such as mould, pet dander, pollen, insect venom, and dust mites can trigger the reaction. Allergy shots help the body become less susceptible to certain triggers by administering little, harmless quantities of them. The immune system gradually builds up an immunity, much like a vaccine, which lessens the symptoms of allergies.
Allergy shot reduces the need for medication for long term, it gets the allergy under control, and it works for variety of allergies by reducing the sensitivity. These benefits of allergy shots are set to boost the demand for it over the projection timeline.
The global market is likely to show high growth over the coming years at a CAGR of 10.4% and reach a global market size of US$ 6.4 Billion by 2033.
“Increasing Incidence of Various Allergy Types”
Different countries have different rates of allergic rhinitis and other allergic diseases.
The frequency of rhinitis tends to rise over time. The global market for allergy shots is expanding as a result of rising instances of allergic disorders and the demand for more targeted and practical treatments.
New allergy disorders are being brought on by changing lifestyles and the adoption of urbanised cultures. Increasing levels of pollution, poor eating habits, and alcohol use can cause a variety of allergic reactions, including food and skin allergies. Consequently, a changing lifestyle may result in a greater need for allergy shots treatments, which will fuel market expansion.
The allergy shot market is constantly evolving with regard to specialised therapeutics, recombinant immunotherapies, and other things. Manufacturers in this sector are constantly using M&A, collaboration, or partnerships to broaden their product offering, clientele, and geographic reach. This enables the participants to grow together, keep their competitive advantage, and satisfy client needs.
For instance, the Nestle Health Science business announced in August 2020 that it would purchase the food allergy product portfolio from Immune Therapeutics.
“Lengthy Treatment Time”
Depending on the nature and stage of the allergy, Allergy Shots is a protracted course of treatment that could last up to 3 to 5 years. Due to lengthy treatment times, age, health, physical location, and financial restrictions, patients typically stop receiving therapy in the middle of the process. This can have a negative effect on market expansion.
Also, because of the adverse side effects of allergy needles and tablets, the market is in decline.
Patients may also have moderate side effects like swelling or redness at the injection site, as well as impacts on their entire body or a specific bodily system.
Why is the United States Market Booming?
“Increasing Investments by the Regional Key Players”
The United States accounted for around 80.8% market share in the North America market in 2022. Increasing investments by companies for advanced product development that are easy to use and provide rapid results to user is also expected to create growth opportunities in the near future for the allergy shots markets.
Will the Germany Be a Lucrative Market for Allergy Shots?
“Increasing Product Launch”
The Germany market held around 27.4% market share of the Europe market in 2022. Increasing product launch is the factor responsible for regional dominance.
ITULAZAX is a practical, once-daily SLIT tablet that is well accepted and appropriate for use at home. It is approved for use in patients with moderate-to-severe allergic rhinitis and/or conjunctivitis caused by pollen from the birch-homologous family of trees, including birch, alder, beech, hazel, hornbeam, and oak, who are 18 to 65 years old and whose symptoms cannot be adequately controlled by symptom-relieving medication.
How is Japan Emerging as a Prominent Market?
“Increasing Prevalence of Allergic Rhinitis”
Japan held a market share of about 44.9% of the East Asia market in 2022. According to the World Health Organization (WHO), allergic rhinitis affects between 10 and 30 percent of individuals worldwide. One of the most common allergy causes is pollen from trees and grass. Ryegrass, Bermuda grass, Timothy grass, and Kentucky bluegrass are the most common grass pollen allergies. Birch, cedar, and oak trees are known to produce extremely allergic pollen.
Which Product is Driving Demand within the Global Market?
“Advantages of Injections for Allergic Reaction Treatment”
The injections segment held around 66.1% share of the total market in 2022. Allergy shots reduce sensitivity to allergens and frequently relieve allergy symptoms for a long time, even after the medication is stopped. For many patients, this makes it a beneficial, affordable therapy strategy.
Allergy injections function similarly to vaccines. The body reacts to an allergen by acquiring immunity to it or a tolerance to it when it is injected in small amounts, and given in steadily increasing doses.
Two stages are involved including build up phase and maintenance phase. The build-up phase entails getting injections of the allergens in escalating doses once or twice a week. This period lasts between three and six months, depending on how frequently the injections are administered.
Which Immunotherapy is Largely in Focus within the Global Market?
“Prevention of Anaphylaxis by Subcutaneous Immunotherapy”
The subcutaneous immunotherapy (SCIT) segment held around 66.1% share of the total market in 2022. For some allergic conditions, allergen-specific subcutaneous immunotherapy is a successful treatment. It should ideally be injected into the upper arm's mid-posterolateral subcutaneous area.
Since it targets the underlying immunological process, subcutaneous immunotherapy (SCIT) is a novel treatment for allergic disease because it alleviates symptoms while altering the allergic condition. In several controlled clinical trials, its effectiveness and safety have been proven in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and stinging insect hypersensitivity.
Which Indication Provides Traction to the Overall Allergy Shots Market?
“Increasing Prevalence of Allergic Rhinitis”
Allergic Rhinitis held around 42.9% share of the total market in 2022. Allergy or hay fever is synonym for allergic rhinitis. Increasing allergic rhinitis globally is the main factor for segment growth. According to an article published in 2022, by Frontiers of Medicine, around 400 million people worldwide suffer from allergic rhinitis (AR), which is a global health concern.
Along with rising urbanization and environmental contaminants, which are some of the primary causes of the disease, the prevalence of AR has increased over time.
Which Allergen is Driving Demand within the Global Market?
“Global Concerns on Impact of Pollen Allegries”
The pollen segment held around 24.6% share of the total market in 2022. Pollen is one of the most frequent causes of seasonal allergies. With allergenic pollen causing rhinitis, asthma, and other allergic diseases, pollinosis is a growing issue. Recent research has demonstrated that there are numerous effects of climate change on aeroallergens and, consequently, on allergy disorders in people.
Due to these factors, the pollen segment is responsible for market expansion worldwide.
Which Distribution Channel Propels the Global Sales in the Market?
“Increasing Hospitals Facilities”
The institutional sales segment held a share of about 58.0% in 2022, within the global market. The institutional sales is further categorized in government hospitals, semi-government hospitals, and private hospitals.
A growth of hospitals around the world is to blame for the segment's domination. With more people seeking treatment for allergies, hospitals held the greatest market share. The segment is also being driven by an increase in the number of allergy cases needing hospitalization. Additionally, the likelihood of early treatment interventions in hospitals has grown due to the rising risk for severe allergic reactions.
Also, there has been a rise in health services worldwide. Hospitals has to provide higher-quality healthcare services as medical tourism increases. During the projected period, it is anticipated that the aforementioned factors would lead to a large increase in the institutional sales category.
The major players are driving market growth with growth strategies like mergers and acquisitions, expansion, new product development, and alliances. Due to the presence of a small number of significant market players, the industry under study is a consolidated market. Aimmune Therapeutics, Hollister Allergy, Leti Pharma, and Merck KGaA are just a few of the internationally and regionally recognized companies whose market shares are examined in the competitive landscape.
Some key instances of development include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the allergy shots market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2033 |
|
Historical Data Available for |
2015 to 2022 |
|
Market Analysis |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Immunotherapy:
Indication:
Allergen:
Distribution Channel:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 2.2 Billion in 2022.
The global market is estimated to be worth US$ 2.4 Billion in 2023.
Sales of the market are set to witness growth at a CAGR of 10.4% and be valued at around US$ 6.4 Billion by 2033.
Demand for the global market increased at an 8.8% CAGR from 2015 to 2022.
Germany, the U.S., the U.K., France, and Spain account for most demand within the market, currently holding around 50.9% market share.
The U.S. accounts for around 80.8% share of the North American market in 2022.
Allergic Rhinitis dominates with 42.9% share of the total market in 2022.
Japan held a market share of about 44.9% of the East Asia market in 2022.
The Germany accounts for around 27.4% share of the Europe in 2022.
Stallergenes Greer, Allergy Therapeutics, Aimmune Therapeutics, Anergis, Arrayit Corporation, Biomay AG, HAL Allergy Group, DBV Technologies, and ALK Abello are the key players within in the global market.
